Jason George specializes in high-stakes complex litigation involving intellectual property, fraud, contract, government, and employment disputes. He has helped a wide range of clients, from leading technology companies to innovative startups to non-profits, by tailoring creative litigation strategies to their individual circumstances and diverse objectives. With experience in all facets of commercial litigation in federal and state court, a quick understanding of emerging technologies, and a talent for in-depth legal analysis, he ardently fights for his clients and has guided them to favorable results on the pleadings, in discovery, and at trial.
Prior to joining Keker, Jason served as a law clerk to former Justice Mariano-Florentino Cuéllar of the California Supreme Court. Preceding that, he served in law clerkships for Judge Lucy H. Koh, then of the U.S. District Court for the Northern District of California, and for Judge John T. Noonan, Jr. of the U.S. Court of Appeals for the Ninth Circuit.
Jason earned his law degree from Stanford Law School and his bachelor’s degree in Molecular Biophysics and Biochemistry from Yale University. During law school, he worked for the Stanford Environmental Law Clinic, where he litigated multiple cases before California and federal courts.
CoStar v. CREXi
We are defending Commercial Real Estate Exchange, Inc. (CREXi), a fast-growing commercial real estate marketplace, against a copyright and unfair competition lawsuit brought by industry giant CoStar.
Rogers v. Lyft
We won two motions to compel arbitration and defeated two related emergency preliminary injunction motions that were brought by Lyft drivers seeking to be classified as employees rather than contractors during the COVID19 crisis. The district court struck the class allegations, granted our arbitration requests, and then remanded plaintiffs’ injunction request to the San Francisco Superior Court to determine if plaintiffs sought public or private injunctive relief. The superior court denied plaintiffs’ preliminary injunction motion, ruling that granting the injunction would result in only modest benefits to a small subset of Lyft drivers, while potentially risking the eligibility of all Lyft drivers to receive substantially greater relief under the Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Jenam Tech v. Google
We defended Google against a series of patent cases alleging that Google’s network protocol infringes Jenam’s patents. A three-judge Federal Circuit panel ordered the district court to transfer the case out of the Western District of Texas, ruling that the court abused its discretion by denying Google’s motion to move the case to California. Following the transfer to San Francisco federal court, the firm achieved a stay of all district court proceedings pending inter partes review proceedings before the PTAB. Google successfully invalidated three Jenam patents and the case subsequently settled.
01/06/2025
Keker, Van Nest & Peters is pleased to announce that the firm has elevated of counsel Sarah Salomon to partner and associate Jason George to of counsel, effective January 1, 2025. Read more
May 01, 2020
A group of Lyft drivers in California lost their latest bid to convince a state court judge to immediately reclassify them as employees with paid sick leave to help fight the spread of Covid-19. Read more
May 01, 2020
San Francisco Superior Judge Ethan Schulman denied a motion that would have reclassified Lyft drivers as employees, so that they can reap the state’s paid sick leave, agreeing with a federal judge who found that such a ruling would jeopardize drivers' access to federal coronavirus relief. Read more
September 16, 2019
The issues at stake in the case illustrate the growing importance of trade secrets protection to life sciences companies and the IP professionals who serve them. Read more
September 09, 2019
Taiwan’s JHL Biotech has agreed to stop developing copycat versions of four Genentech biologics as part of a deal to end high-stakes trade secrets litigation. Read more
September 09, 2019
Genentech reaches a settlement agreement with JHL Biotech, which sees the latter cease development of biosimilars to Genentech’s products. Read more